Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers

Background Candidate biomarkers have been identified for clear cell renal cell carcinoma (ccRCC) patients, but most have not been validated. Objective To validate published ccRCC prognostic biomarkers in an independent patient cohort and to assess intratumour heterogeneity (ITH) of the most promising markers to guide biomarker optimisation. Design, setting, and participants Cancer-specific survival (CSS) for each of 28 identified genetic or transcriptomic biomarkers was assessed in 350 ccRCC patients. ITH was interrogated in a multiregion biopsy data set of 10 ccRCCs. Outcome measurements and statistical analysis Biomarker association with CSS was analysed by univariate and multivariate analyses. Results and limitations A total of 17 of 28 biomarkers (TP53 mutations; amplifications of chromosomes 8q, 12, 20q11.21q13.32, and 20 and deletions of 4p, 9p, 9p21.3p24.1, and 22q; low EDNRB and TSPAN7 expression and six gene expression signatures) were validated as predictors of poor CSS in univariate analysis. Tumour stage and the ccB expression signature were the only independent predictors in multivariate analysis. ITH of the ccB signature was identified in 8 of 10 tumours. Several genetic alterations that were significant in univariate analysis were enriched, and chromosomal instability indices were increased in samples expressing the ccB signature. The study may be underpowered to validate low-prevalence biomarkers. Conclusions The ccB signature was the only independent prognostic biomarker. Enrichment of multiple poor prognosis genetic alterations in ccB samples indicated that several events may be required to establish this aggressive phenotype, catalysed in some tumours by chromosomal instability. Multiregion assessment may improve the precision of this biomarker. Patient summary We evaluated the ability of published biomarkers to predict the survival of patients with clear cell kidney cancer in an independent patient cohort. Only one molecular test adds prognostic information to routine clinical assessments. This marker showed good and poor prognosis results within most individual cancers. Future biomarkers need to consider variation within tumours to improve accuracy.

[1]  Terence P. Speed,et al.  A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6 , 2009, Bioinform..

[2]  G. Hommel,et al.  Survival analysis: part 15 of a series on evaluation of scientific publications. , 2011, Deutsches Arzteblatt international.

[3]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[4]  Gyan Bhanot,et al.  Abstract 1996: Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns , 2010 .

[5]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Belldegrun,et al.  Basic research in kidney cancer. , 2011, European urology.

[7]  P. Kapur,et al.  Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. , 2013, The Lancet. Oncology.

[8]  M. Kattan,et al.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.

[9]  Arianna Di Napoli,et al.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. , 2009, Cancer research.

[10]  E. Jonasch,et al.  Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis , 2011, Modern Pathology.

[11]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[12]  Henrik Bengtsson,et al.  CalMaTe: a method and software to improve allele-specific copy number of SNP arrays for downstream segmentation , 2012, Bioinform..

[13]  Holger Moch,et al.  VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma , 2002, The Journal of pathology.

[14]  S. Goldman,et al.  Hematology/Oncology Clinics of North America , 2020, Hematology/Oncology Clinics of North America.

[15]  J. Hackermüller,et al.  CD31, EDNRB and TSPAN7 are promising prognostic markers in clear‐cell renal cell carcinoma revealed by genome‐wide expression analyses of primary tumors and metastases , 2012, International journal of cancer.

[16]  A. Belldegrun,et al.  Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma , 2010, Cancer.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[18]  A. Poustka,et al.  Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. , 2001, Cancer research.

[19]  Liang Cheng,et al.  Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma , 2008, Modern Pathology.

[20]  J. Kim,et al.  Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma , 2005 .

[21]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[22]  P. Rehak,et al.  External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. , 2010, European urology.

[23]  P. A. Futreal,et al.  State of the Science: An Update on Renal Cell Carcinoma , 2012, Molecular Cancer Research.

[24]  Mary Goldman,et al.  The UCSC Genome Browser database: extensions and updates 2013 , 2012, Nucleic Acids Res..

[25]  A. Belldegrun,et al.  Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma , 2012, Cancer.

[26]  H. Moch,et al.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. , 2009, European urology.

[27]  Terence P. Speed,et al.  TumorBoost: Normalization of allele-specific tumor copy numbers from a single pair of tumor-normal genotyping microarrays , 2010, BMC Bioinformatics.

[28]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[29]  R. Tardanico,et al.  Prognostic value of cytogenetic analysis in clear cell renal carcinoma: a study on 131 patients with long-term follow-up. , 2010, Anticancer research.

[30]  M. Fernö,et al.  Prognostic implications of cytogenetic findings in kidney cancer. , 1997, British journal of urology.

[31]  R. Thompson,et al.  Potential role of genetic markers in the management of kidney cancer. , 2013, European Urology.

[32]  D. Lindgren,et al.  Effects of TGF-β signaling in clear cell renal cell carcinoma cells. , 2013, Biochemical and biophysical research communications.

[33]  Benjamin J. Raphael,et al.  Mutational landscape and significance across 12 major cancer types , 2013, Nature.

[34]  Joanna H Shih,et al.  Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Z. Szallasi,et al.  Parallel evolution of tumour subclones mimics diversity between tumours , 2013, The Journal of pathology.

[36]  W. Kimryn Rathmell,et al.  Renal Cell Carcinoma: Where Will the State-of-the-Art Lead Us? , 2010, Current oncology reports.

[37]  C. Lohse,et al.  External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma. , 2006, The Journal of urology.

[38]  J. Cheville,et al.  Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness , 2005, Clinical Cancer Research.

[39]  M Mazumdar,et al.  Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Bühlmann,et al.  Integrative genome-wide expression profiling identifies three distinct molecular subgroups of renal cell carcinoma with different patient outcome , 2012, BMC Cancer.

[41]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[42]  Nicolai J. Birkbak,et al.  Chromosomal instability confers intrinsic multidrug resistance. , 2011, Cancer research.

[43]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. Yousef,et al.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma , 2009, Molecular Cancer.

[45]  B. Williams,et al.  Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. , 2009, The Journal of urology.

[46]  R. Arceci.  Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[47]  C. Swanton,et al.  Cancer chromosomal instability: therapeutic and diagnostic challenges , 2012, EMBO reports.

[48]  F. Waldman,et al.  Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. , 1996, Cancer research.

[49]  Kazuki Kobayashi,et al.  VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. , 2002, Journal of the National Cancer Institute.

[50]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[51]  Jiri Bartek,et al.  Replication stress links structural and numerical cancer chromosomal instability , 2013, Nature.

[52]  P. Tang,et al.  Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far. , 2011, Hematology/oncology clinics of North America.

[53]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[54]  Wanling Xie,et al.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Robert Tibshirani,et al.  Gene Expression Profiling Predicts Survival in Conventional Renal Cell Carcinoma , 2005, PLoS medicine.

[56]  C. Sander,et al.  Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2: A Report by MSKCC and the KIRC TCGA Research Network , 2013, Clinical Cancer Research.

[57]  C. Schwaenen,et al.  Identification of genomic alterations associated with metastasis and cancer specific survival in clear cell renal cell carcinoma. , 2011, The Journal of urology.

[58]  A. Belldegrun,et al.  Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  H. Aburatani,et al.  Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.

[60]  M. Kattan,et al.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. , 2005, The Journal of urology.

[61]  A. Belldegrun,et al.  Deletions of chromosomes 3p and 14q molecularly subclassify clear cell renal cell carcinoma , 2013, Cancer.

[62]  Ying Huang,et al.  A three‐gene expression signature model to predict clinical outcome of clear cell renal carcinoma , 2008, International journal of cancer.

[63]  Martin Vingron,et al.  Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.